中国血吸虫病防治杂志(中英文) ›› 2025, Vol. 37 ›› Issue (3): 247-254.

• 论著 • 上一篇    下一篇

2006—2023年甘肃省肝细粒棘球蚴病患者手术疗效评估

程茜茜1△,冯宇2△,王旭1,王芝依1,雷家希1,姜明哲1,杨国兵2,张小娟2,杨诗杰1,王立英1*   

  1. 1 中国疾病预防控制中心寄生虫病预防控制所(国家热带病研究中心)、传染病溯源预警与智能决策全国重点实验室、国家卫生健康委员会寄生虫病原与媒介生物学重点实验室、WHO热带病合作中心、科技部国家级热带病国际联合研究中心(上海 200025);2 甘肃省疾病预防控制中心(甘肃 兰州 730000)
  • 出版日期:2025-06-25 发布日期:2025-07-14
  • 通讯作者: 王立英 wangliyingcdc@163.com
  • 作者简介:程茜茜,女,硕士研究生。研究方向: 流行病与卫生统计学 冯宇,男,研究员。研究方向:寄生虫病防治研究

Evaluation of surgical efficacy in patients with hepatic cystic echinococcosis in Gansu Province from 2006 to 2023

CHENG Xixi1△, FENG Yu2△, WANG Xu1, WANG Zhiyi1, LEI Jiaxi1, JIANG Mingzhe1, YANG Guobing2, ZHANG Xiaojuan2, YANG Shijie1, WANG Liying1*   

  1. 1 National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Center for Tropical Diseases Research), National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases; National Health Commission Key Laboratory of Parasite and Vector Biology, WHO Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases, Ministry of Science and Technology, Shanghai 200025, China; 2 Gansu Provincial Center for Disease Control and Prevention, Lanzhou, Gansu 730000, China
  • Online:2025-06-25 Published:2025-07-14

关键词: 肝细粒棘球蚴病, 手术患者, 疗效评估, 治愈率, 复发率

Abstract: Objective To evaluate the therapeutic efficacy for surgical treatments among patients with hepatic cystic echinococcosis in Gansu Province, so as to provide insights into optimization of the diagnosis and treatment strategies against hepatic cystic echinococcosis. Methods The demographic and clinical data of all echinococcosis cases included in central government fiscal transfer payment program for echinococcosis control and undergoing surgical treatments in Gansu Province from 2006 to 2023 were captured. Hepatic cystic echinococcosis patients with complete medical records and follow⁃up data were included in the study, and patients' characteristics, including hospital where patients received diagnosis and treatment, methods of case identification, year of surgery, classification of lesions, number of lesions, size of lesions, course of disease, surgical methods, and post⁃surgical follow⁃up data. The cure and recurrence of hepatic cystic echinococcosis were evaluated according to the Guidelines for Management of Echinococcosis Patients in the Central Government Fiscal Transfer Payment Program, and the cure and recurrent rates were calculated. Results Data were collected from 1 686 surgical patients with hepatic cystic echinococcosis. According to the inclusion and exclusion criteria, 1 222 hepatic cystic echinococcosis patients undergoing surgical treatments were included during the period from 2006 to 2022, including 1 166 cured patients (95.42%) and 88 patients with post⁃surgical recurrence (7.20%), and the cure rate of surgical treatments appeared a tendency towards a rise among patients with hepatic cystic echinococcosis from 2008 to 2022 ([χ2]trend = 19.39, P < 0.05). The cure rates of hepatic cystic echinococcosis were 100% (177/177), 94.81% (128/135) and 94.62% (861/910) among patients detected through regular physical examinations, screened by the central government fiscal transfer payment program for echinococcosis control, and those who passively sought healthcare services, respectively ([χ2] = 9.95, P < 0.05). The cure rates of hepatic cystic echinococcosis were 95.96% (1 046/1 090) among patients with a disease course of 2 years and less and 90.90% (120/132) among patients with a disease course of over 2 years ([χ2] = 6.87, P < 0.05), and there were significant differences in the cure rates among patients with hepatic cystic echinococcosis in terms of number of lesions ([χ2] = 24.44, P < 0.05) and surgical methods (P < 0.05). The cure rate of hepatic cystic echinococcosis patients was significantly higher following initiation of the central government fiscal transfer payment program for echinococcosis control (96.06%, 1 096/1 141) than before the program (86.42%, 70/81) ([χ2] = 16.06, P < 0.05), and the cure rate of hepatic cystic echinococcosis patients was significantly higher in designated hospitals (96.48%, 741/768) than in non⁃designated hospitals (93.37%, 366/392) ([χ2] = 5.78, P < 0.05). The median follow⁃up period was 4 (interquartile range, 7) years among 1 222 hepatic cystic echinococcosis patients undergoing surgical treatments. The recurrent rate of hepatic cystic echinococcosis appeared a tendency towards a decline from 2008 to 2022 ([χ2]trend = 36.86, P < 0.05), with a reduction from 23.08% (9/39) in 2008 to 1.85% (1/54) in 2021, and the post⁃surgical recurrence rate of hepatic cystic echinococcosis was lower following initiation of the central government fiscal transfer payment program for echinococcosis control (5.87%, 67/1 141) than before the program (25.93%, 21/81) ([χ2] = 45.51, P < 0.05). In addition, the post⁃surgical recurrence rate of hepatic cystic echinococcosis was higher in non⁃designated hospitals (10.46%, 41/392) than in designated hospitals (5.60%, 43/768) ([χ2] = 9.12, P < 0.05), and there was a significant difference in the post⁃surgical recurrence rate among patients with hepatic cystic echinococcosis in terms of surgical methods (P < 0.05), with the highest recurrence rate (11.54%) seen among patients undergoing percutaneous fine⁃needle aspiration of cyst fluids⁃based surgical procedures (P < 0.05). Conclusion Since the initiation of the central government fiscal transfer payment program for echinococcosis control in Gansu Province in 2006, an increase in the surgical cure rate and a reduction in the recurrence of hepatic cystic echinococcosis had been found among patients with hepatic cystic echinococcosis, indicating a high overall therapeutic efficacy.

Key words: Hepatic cystic echinococcosis, Surgical patient, Therapeutic efficacy evaluation, Cure rate, Recurrence rate